Silver Book Fact

After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who received traditional chemotherapy.

Aspinall, M and R Hamermesh. Realizing the Promise of Personalized Medicine. Harvard Bus Rev. 2007; 85(10): 108-17. https://hbr.org/2007/10/realizing-the-promise-of-personalized-medicine

Reference

Title
Realizing the Promise of Personalized Medicine
Publication
Harvard Bus Rev
Publication Date
2007
Authors
Aspinall, M and R Hamermesh
Volume & Issue
Volume 85, Issue 10
Pages
108-17
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • According to the Pharmaceutical Research and Manufacturers of America, a number of vaccines are being studied that would cause the body’s own immune system to fight cancer after it has…  
  • The Impact of Personalized Medicine on Cancer Survival in Years  
  • Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient.   
  • The increase in the stock of cancer drugs from 1975 to 1995 accounted for about 50 to 60 percent of the increase in age-adjusted survival rates in the first 6…  
  • Approximately one third of men diagnosed with prostate cancer will opt for surgical treatment.